Videos

FDA Approves Low-Dose MRI Contrast Agent Gadoquatrane

FDA Approves Low-Dose MRI Contrast Agent Gadoquatrane

Published: | Updated:

Indicated for the detection and visualization of abnormal vascularity in the central nervous system (CNS) and non-CNS body regions, gadoquatrane provides 60 percent less gadolinium dosing in comparison to other macrocyclic gadolinium (Gd)-based contrast agents (mGBCAs).

Addressing Challenges in Radiology Reporting

In a recent interview, Nina Kottler, MD, discussed the challenges with traditional radiology reporting, its impact on cognitive load and the recently launched AI-enabled platform Mosaic Reporting.

Should There Be Greater Oversight of MRI Safety?

In recent interviews, Emanuel Kanal, MD, and Tobias Gilk, MRSO, MRSE, noted a lack of point-of-care safety requirements for MRI, a lack of state oversight, and a prevailing lack of minimum standards overall for MRI safety.